Literature DB >> 2900146

Haemodynamic effects of short-term treatment with bopindolol in essential hypertension.

P Fitscha1, W Meisner, G Brandstetter, B Tiso.   

Abstract

Ten patients (mean age 53 years) with essential hypertension have been studied at rest and during exercise following oral treatment for 6 weeks with a new beta-adrenoceptor blocking agent, bopindolol. The treatment caused a significant decrease in systolic and diastolic arterial blood pressure and heart rate, both at rest and during exercise. Stroke volume fell, too, and therefore so did cardiac output, whereas the systemic vascular resistance was increased. Left ventricular filling pressure was elevated both at rest and during exercise following bopindolol therapy. However, a different haemodynamic pattern was noted in patients with elevated total peripheral resistance prior to therapy (Group 1) compared to patients with normal or subnormal peripheral resistance (Group 2). A decrease in systemic vascular resistance seemed to be the cause of the fall in blood pressure in Group 1, as the expected increase in vascular resistance did not occur, whereas a reduction in cardiac output was of greater importance in Group 2. During exercise the lowering of arterial blood pressure in both groups was mediated by a reduction in cardiac output.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900146     DOI: 10.1007/bf00542445

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work.

Authors:  G Johnsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Relationship of the pulmonary artery end-diastolic pressure to the left ventricular end-diastolic and mean filling pressures in patients with and without left ventricular dysfunction.

Authors:  R E Falicov; L Resnekov
Journal:  Circulation       Date:  1970-07       Impact factor: 29.690

3.  Hemodynamics in juvenile hypertension with special reference to the response to propranolol.

Authors:  K Kuramoto; K Murata; Y Yazaki; M Ikeda; K Nakao
Journal:  Jpn Circ J       Date:  1968-07

4.  Hemodynamic response to exercise in patients with arterial hypertension.

Authors:  R Sannerstedt
Journal:  Acta Med Scand Suppl       Date:  1966

5.  Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.

Authors:  W Schiess; D Welzel; R Gugler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Relationship between clinical severity of disease and hemodynamic patterns in essential hypertension.

Authors:  C T Bello; R W Sevy; C Harakal; P N Hillyer
Journal:  Am J Med Sci       Date:  1967-02       Impact factor: 2.378

7.  Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.

Authors:  P van Brummelen; F R Bühler; F W Amann; P Bolli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients.

Authors:  P Van Brummelen; P Bolli; M I Koolen; H B Staehelin; F R Bühler
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

9.  Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting.

Authors:  D R Turner; F J Goodwin; A R Knight; D W Littlejohns; V L Sharman; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

10.  Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age.

Authors:  U L Hulthén; P van Brummelen; F W Amann; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

View more
  1 in total

Review 1.  Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  D W Harron; K L Goa; H D Langtry
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.